RxDoctor Payments DataLook up a doctor →

Abbas Shehadeh, MD

Cardiovascular Disease · West Orange, NJNPI 1215900774

Payments from drug & device makers

$356,027in general payments, 2019–2025

Across 825 payments — averaging $431.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$100K
  • Amgen$60K
  • Biotronik Inc.$40K
  • Surmodics, Inc.$38K
  • American Regent$37K
  • CSL Behring$34K
  • plus $47K from 41 others

What the payments were for

  • Speaking & faculty fees$3,00011%
  • Travel & lodging$8,03228%
  • Food & beverage$17,14761%
  • Education$810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$356,027 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$287,904
Medicare patients
459
Services billed
2,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan107$113,846
EliquisApixaban107$109,684
BrilintaTicagrelor94$85,977
FarxigaDapagliflozin Propanediol82$61,075
JardianceEmpagliflozin63$58,638
Repatha PushtronexEvolocumab68$46,856
OzempicSemaglutide30$37,740
VerquvoVericiguat21$24,667
Repatha SureclickEvolocumab41$23,974
MultaqDronedarone Hcl18$18,861
JanumetSitagliptin Phos/Metformin Hcl24$17,862
VascepaIcosapent Ethyl47$17,595
JanuviaSitagliptin Phosphate14$17,513
Repatha SyringeEvolocumab13$6,238
Spiriva RespimatTiotropium Bromide11$5,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$22,392$147,052176 claims
NovartisEntresto$100,156$113,846107 claims
PfizerEliquis$162$109,684107 claims
Boehringer IngelheimJardiance, Spiriva Respimat$434$64,45974 claims
MerckVerquvo, Janumet, Januvia$566$60,04159 claims
Novo NordiskOzempic$763$37,74030 claims
Sanofi-aventis U.S. LLCMultaq$147$18,86118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →